Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Doris Weilert"'
Autor:
Karthick Vishwanathan, Inmaculada Sanchez‐Simon, Bhumsuk Keam, Nicolas Penel, Maria deMiguel‐Luken, Doris Weilert, Andrew Mills, Marcelo Marotti, Martin Johnson, Alain Ravaud
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Abstract Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy
Externí odkaz:
https://doaj.org/article/3def02ff83134171b001fbbb4b3c90e2
Autor:
Sang We Kim, Emiliano Calvo, G. Laus, Jong Seok Lee, Victor Moreno, Doris Weilert, Karthick Vishwanathan, Helen Mann, Javier de Castro Carpeño
Publikováno v:
The Journal of Clinical Pharmacology. 59:1099-1109
Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations. It is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae491645cd6e69cff26248f5e1219a7e
https://doi.org/10.1002/jcph.1403
https://doi.org/10.1002/jcph.1403
Autor:
Nicolas Penel, Karthick Vishwanathan, Alain Ravaud, Bhumsuk Keam, Martin Johnson, Inmaculada Sanchez-Simon, Maria de Miguel-Luken, Doris Weilert, Andrew Mills, Marcelo Marotti
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy in non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36dfb55310a91895d57f00b9e21d0c92
https://doi.org/10.1002/prp2.613
https://doi.org/10.1002/prp2.613
Autor:
Karthick Vishwanathan, Jong Seok Lee, Nicolas Isambert, Johan Vansteenkiste, Tobias Arkenau, Doris Weilert, Noemi Reguart Aransay, R. Donald Harvey, Khanh Bui, Paul A. Dickinson, Karen Thomas, Karen So
Publikováno v:
British Journal of Clinical Pharmacology. 84:2877-2888
Aim We report on two Phase 1, open-label, single-arm studies assessing the effect of osimertinib on simvastatin (CYP3A substrate) and rosuvastatin (breast cancer resistance protein substrate [BCRP] substrate) exposure in patients with advanced epider
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c6355ba27a1dfb1ba2a8d5317304e34
https://doi.org/10.1111/bcp.13753
https://doi.org/10.1111/bcp.13753
Autor:
Hye Ryun Kim, Paul A. Dickinson, Khanh Bui, Karthick Vishwanathan, Doris Weilert, R. Donald Harvey, Anne-Marie C. Dingemans, Matthew G Krebs, Karen So, Yuh Min Chen, James Chih-Hsin Yang, Karen Thomas, Joo Hang Kim, Javier de Castro Carpeño
Publikováno v:
British Journal of Clinical Pharmacology. 84:1156-1169
Aims We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor-tyrosine kinase inhibitor osimertinib, in patients with advanced non-small cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0be5bb70a50cd4ea3ccac9ae5cb4bd10
https://doi.org/10.1111/bcp.13534
https://doi.org/10.1111/bcp.13534
Autor:
Karthick, Vishwanathan, Paul A, Dickinson, Karen, So, Karen, Thomas, Yuh-Min, Chen, Javier, De Castro Carpeño, Anne-Marie C, Dingemans, Hye Ryun, Kim, Joo-Hang, Kim, Matthew G, Krebs, James, Chih-Hsin Yang, Khanh, Bui, Doris, Weilert, R Donald, Harvey
Publikováno v:
British journal of clinical pharmacology. 84(6)
AIMS: We investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) on the pharmacokinetics of the epidermal growth factor receptor‐tyrosine kinase inhibitor osimertinib, in patients with advanced non‐small cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22b730347dc411382e7c30292afd7fce
https://pubmed.ncbi.nlm.nih.gov/29381826
https://pubmed.ncbi.nlm.nih.gov/29381826
Autor:
Eleanor Lisbon, Karen So, Alastair Greystoke, Khanh Bui, Victor Moreno, Doris Weilert, Timothy A. Yap, Karen Thomas, Ruth Plummer, Karthick Vishwanathan, Philippe A. Cassier, Paul A. Dickinson
Publikováno v:
Journal of clinical pharmacology. 58(4)
Two phase 1, open-label studies assessed the impact of food or gastric pH modification (omeprazole) on the exposure and safety/tolerability of osimertinib and its metabolites. The food effect study was an open-label, 2-period crossover study in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d08786faa3429bb780112e850ab4aa31
https://pubmed.ncbi.nlm.nih.gov/29178442
https://pubmed.ncbi.nlm.nih.gov/29178442
Autor:
Nicolas Isambert, Johan Vansteenkiste, R. Donald Harvey, Doris Weilert, Saeed Rafii, Karen Thomas, Karthick Vishwanathan, Paul A. Dickinson, Karen So, Khanh Bui
Publikováno v:
Journal of Clinical Oncology. 34:e14098-e14098
e14098Background: Osimertinib is a potent, oral, irreversible EGFR-TKI with efficacy in pts with EGFR-TKI sensitizing (EGFRm) and T790M mutation positive advanced NSCLC. In vitro data show osimerti...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fab5cd08a08f90d556ff6ec78a46b0c
https://doi.org/10.1200/jco.2016.34.15_suppl.e14098
https://doi.org/10.1200/jco.2016.34.15_suppl.e14098
Autor:
Paul A. Dickinson, R. Donald Harvey, Matthew G Krebs, Khanh Bui, Doris Weilert, Karen Thomas, James Chih-Hsin Yang, Karen So, Karthick Vishwanathan, Jong Seok Lee
Publikováno v:
Journal of Clinical Oncology. 34:e14100-e14100
e14100Background: Osimertinib is a potent, oral, irreversible EGFR-TKI with efficacy in pts with EGFR-TKI sensitizing (EGFRm) and T790M mutation positive advanced NSCLC. Metabolism of osimertinib a...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faaa9a7a8a5e50f53b80b904064aacd0
https://doi.org/10.1200/jco.2016.34.15_suppl.e14100
https://doi.org/10.1200/jco.2016.34.15_suppl.e14100
Autor:
Doris Weilert
Publikováno v:
Pharmaceutical Sciences Encyclopedia ISBN: 9780470571224
Pharmaceutical Sciences Encyclopedia
Pharmaceutical Sciences Encyclopedia
Pharmacokinetic (PK) data in special populations are registration requirements if the target patient population is likely to include special population(s). U.S. and European regulatory guidelines require formal PK studies in geriatric, RI, and HI imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eea6055a430aa628d6b633af3e3bee85
https://doi.org/10.1002/9780470571224.pse223
https://doi.org/10.1002/9780470571224.pse223
